Emerging evidence suggests that malignant tumors are composed of a small subset of distinct cancer cells, termed “cancer stem cells” (typically less than 5% of total cancer cells based on cell surface marker expression), which have great proliferative potential, as well as more differentiated cancer cells, which have very limited proliferative potential. Data have been provided to support the existence of cancer stem cells in several different types of cancer, including human blood, brain, prostate, ovarian, melanoma, colon, and breast cancers. We have recently reported the identification of a subpopulation of pancreatic cancer cells that express the cell surface markers CD44+CD24+ESA+ (0.2–0.8% of all human pancreatic cancer cells) that function as pancreatic cancer stem cells. The CD44+CD24+ESA+ pancreatic cancer cells are highly tumorigenic and possess the stem cell-like properties of self-renewal and the ability to produce differentiated progeny. Pancreatic cancer stem cells also demonstrate upregulation of molecules important in developmental signaling pathways, including sonic hedgehog and the polycomb gene family member Bmi-1. Of clinical importance, cancer stem cells in several tumor types have shown resistance to standard therapies and may play a role in treatment failure or disease recurrence. Identification of pancreatic cancer stem cells and further elucidation of the signaling pathways that regulate their growth and survival may provide novel therapeutic approaches to treat pancreatic cancer, which is notoriously resistant to standard chemotherapy and radiation.
Pancreatic cancer stem cells niche CD44 ESA CD24 NOD/SCID xenografts tumorigenic potential self-renewal
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Hoyert DL, Heron MP, Murphy SL, Kung HC. (2006) Deaths: final data for 2003. Natl Vital Stat Rep 19: 1–120.Google Scholar
Bonnet D, Dick JE. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 3: 730–737.PubMedCrossRefGoogle Scholar
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. (1994) A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 17: 645–648.CrossRefGoogle Scholar
Matsui W, Huff CA, Wang Q, et al. (2004) Characterization of clonagenic multiple myeloma cells. Blood 103: 2332–2336.PubMedCrossRefGoogle Scholar
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983–3988.PubMedCrossRefGoogle Scholar
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23): 10946–10951.PubMedCrossRefGoogle Scholar
O’Brien CA, Pollett A, Gallinger S, Dick JE. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123): 106–110.PubMedCrossRefGoogle Scholar
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111–115.PubMedCrossRefGoogle Scholar
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3): 1030–1037.PubMedCrossRefGoogle Scholar
Hahn SA, Seymour AB, Hoque AT, et. al. (1995) Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55: 4670–4675.PubMedGoogle Scholar
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. (2006) Cancer stem cells – Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66(19): 9339–9344.PubMedCrossRefGoogle Scholar